Decheng Capital is a venture capital firm that provides capital to early and growth stage life science companies.
Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 9, 2021
Mammoth Biosciences
|
Series D | $150M | Biotechnology | — |
May 13, 2021
Cue
|
Series Unknown | $235M | Health Care | — |
Mar 22, 2021
EpimAb Biotherapeutics
|
Series C | $120M | Biopharma | — |
Nov 4, 2020
Mammoth Biosciences
|
Series C | $45M | Biotechnology | — |
Jun 10, 2020
Cue
|
Series C | $102.60M | Health Care | — |